Rhenman & Partners Asset Management’s West Pharmaceutical WST Stock Holding History

Rhenman & Partners Asset Management’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,000	Closed	-$1.93M	–	104
2025 Q4	$1.93M	Buy	+7,000	New	+$1.91M	0.18%	88
2024 Q1	–	Sell	-9,000	Closed	-$3.17M	–	94
2023 Q4	$3.17M	Hold	9,000	–	–	0.32%	67
2023 Q3	$3.38M	Hold	9,000	–	–	0.36%	62
2023 Q2	$3.44M	Sell	9,000 -6,000	-40%	-$2.14M	0.36%	65
2023 Q1	$5.11M	Sell	15,000 -10,000	-40%	-$2.92M	0.56%	56
2022 Q4	$5.88M	Buy	25,000 +8,000	+47%	+$1.9M	0.61%	54
2022 Q3	$3.91M	Buy	+17,000	New	+$5.18M	0.41%	67

Other funds holding WST

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Rhenman & Partners Asset Management's WST Position: Q1 2026 in Review

Rhenman & Partners Asset Management sold out of West Pharmaceutical (WST) in Q1 2026, closing a stake of 7,000 shares — an estimated $1.93M sold.

Rhenman & Partners Asset Management first reported a position in WST in Q3 2022 and held it in 7 quarters. The position peaked at $5.88M in Q4 2022. 755 funds tracked by Wall St. Rank hold WST as of Q1 2026.

Rhenman & Partners Asset Management reported no remaining West Pharmaceutical position as of Q1 2026 after selling out during the quarter.
Rhenman & Partners Asset Management sold 7,000 West Pharmaceutical shares in Q1 2026, an estimated $1.93M.
Rhenman & Partners Asset Management first reported a position in West Pharmaceutical in Q3 2022 and held it in 7 quarters.
Rhenman & Partners Asset Management's West Pharmaceutical position peaked at $5.88M in Q4 2022.
755 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2026, filed 14 May 2026.